Monitor for discovery developments and any settlement signals. The surviving UCL conspiracy claim against the Aequita pharmacy defendants keeps meaningful pressure on the compounding ecosystem that Lilly alleges is infringing on its GLP-1 franchise. However, the dismissal of Lanham Act conspiracy claims with prejudice limits the federal remedy and may reduce settlement leverage. The stock is unlikely to move materially on this procedural ruling alone — the next catalyst would be a summary judgment ruling or trial date.
Price Chart
Executive Summary
Eli Lilly's false advertising lawsuit against Mochi Health and compounding pharmacies survives in part. The court denied dismissal of the UCL conspiracy claim against the Aequita pharmacy defendants (allowing the case to proceed on the core theory that they knowingly participated in an unlawful corporate practice of medicine scheme), but dismissed the Lanham Act false advertising conspiracy claims against all defendants with prejudice (narrowing the scope of the case). This is a modest procedural win for Lilly — the case continues against key defendants on a significant state-law theory, but the federal false advertising conspiracy claims are permanently gone, limiting potential remedies and discovery scope. The ruling is a probability shifter, not a final outcome, and the financial exposure remains unquantified in the opinion.
Court Ruling Details
Key Facts
- Court denied motion to dismiss UCL conspiracy claim against Aequita Pharmacy and Aequita Corporation defendants — case proceeds on that theory.
- Court dismissed with prejudice Lanham Act false advertising conspiracy claims against all defendants (Mochi Medical and Aequita entities) — Lilly cannot replead without newly discovered facts.
- Ruling is interlocutory (motion to dismiss on a second amended complaint); no damages awarded or pleaded amount stated in the opinion.
- Lilly's core allegations of false advertising and corporate practice of medicine against Mochi Health Corp. remain intact and were not challenged in this motion.
- Case is in the Northern District of California before Judge Jacqueline Scott Corley.
Financial Impact
No damages awarded or pleaded amount stated in the opinion. The ruling is procedural — it narrows the scope of potential liability but does not quantify exposure.
Risk Factors
- Case could expand if discovery reveals additional defendants or broader conspiracy
- Adverse ruling on UCL claim could create precedent for other branded drug makers suing compounding pharmacies
- No immediate financial exposure quantified in the opinion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2e8cc32480-LLY |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | Press Release | $1,115.70 $1,152.93 | ▲ +3.34% | ▲ +3.56% | $1,140.66 (+2.24%) |
Sep 8, 2026 24d ago | Court Ruling | $1,123.91 $1,138.28 | ▲ +1.28% | ▲ +1.94% | $1,140.66 (+1.49%) |
Aug 18, 2026 6w ago | Insider Cluster | $1,225.73 $1,233.66 | ▲ +0.65% | ▲ +0.85% | $1,140.66 (−6.94%) |
Aug 11, 2026 7w ago | Insider Cluster | $1,215.02 $1,225.73 | ▲ +0.88% | ▲ +1.29% | $1,140.66 (−6.12%) |
Aug 7, 2026 8w ago | Court Ruling | $1,185.71 $1,180.16 | ▼ −0.47% | ▼ −0.87% | $1,140.66 (−3.80%) |
Aug 5, 2026 8w ago | 8-K | $1,169.86 $1,220.28 | ▲ +4.31% | ▲ +3.96% | $1,140.66 (−2.50%) |
Aug 4, 2026 8w ago | Court Ruling | $1,115.68 $1,215.02 | ▲ +8.90% | ▲ +9.00% | $1,140.66 (+2.24%) |
Jul 31, 2026 9w ago | Court Ruling | $1,148.84 $1,185.71 | ▼ −3.21% | ▲ +0.30% | $1,140.66 (+0.71%) |
Jul 30, 2026 9w ago | Court Ruling | $1,154.97 $1,191.94 | ▲ +3.20% | ▼ −0.42% | $1,140.66 (−1.24%) |
Jul 22, 2026 10w ago | Press Release | $1,163.01 $1,210.02 | ▲ +4.04% | ▲ +6.44% | $1,140.66 (−1.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access